Amylin's experience was somewhere in between Agouron's and DepoTech's. The company decided to perform more Phase III trials on pramlintide, its diabetes drug, to clarify results from clinical trials announced in August. Pramlintide was found to have effect on Type I but not Type II diabetes, and the stock cratered by 42 percent on Aug. 18. Co. The stream of companies looking for space hasn't slowed as of yet, Jacobs says, despite continuing predictions that the industry will consolidate. John Burnham Broker Brent Jacobs.
Money continues to flow into the biotech sector - albeit selectively.
A hybrid German-American company, Sequenom competes in the hot field of DNA chips. The super chips will diagnose genetic conditions and infections in minutes instead of days. The allure attracts savvy investors such as local biotech pioneer Howard Birndorf, who founded Nanogen Inc. on that principle. That's another story, too long to tell here. The science behind Sequenom comes from Germany, but the entrepreneurship is pure San Diego.